Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China
Md Mahmudul Islam,Yaoju Tan,H M Adnan Hameed,Yang Liu,Chiranjibi Chhotaray,Xiaoyin Cai,Zhiyong Liu,Zhili Lu,Shuai Wang,Xingshan Cai,Biyi Su,Xinjie Li,Shouyong Tan,Jianxiong Liu,Tianyu Zhang,H.M. Adnan Hameed
DOI: https://doi.org/10.1016/j.jgar.2020.02.019
IF: 4.349
2020-09-01
Journal of Global Antimicrobial Resistance
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>Amikacin is the only second-line injectable (SLI) antituberculosis (anti-TB) drug still recommended for multidrug-resistant tuberculosis (MDR-TB) treatment when a short MDR-TB regimen is designed. Mutations in <em>rrs</em> and <em>eis</em> are reported to be associated with resistance to amikacin. In this study, we investigated the incidence of <em>rrs</em>, <em>eis</em>, <em>tap</em>, and <em>whiB7</em> mutations in amikacin-resistant <em>Mycobacterium tuberculosis</em> clinical isolates to find the proportion of different mutations related to amikacin resistance.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>A total of 395 clinical isolates of <em>M. tuberculosis</em> were performed for phenotypic drug susceptibility testing (DST) to ten drugs with Löwenstein-Jensen (L-J) method. We sequenced <em>rrs</em>, <em>eis</em>, <em>tap</em>, and <em>whiB7</em> genes in 178 <em>M. tuberculosis</em> clinical isolates (89 amikacin-resistant isolates and 89 out of 306 amikacin-susceptible ones).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Our data showed 22.53% (89/395) <em>M. tuberculosis</em> clinical isolates were resistant to amikacin. Of the 89 amikacin-resistant isolates, 89.89% (80/89) were MDR-TB of which 12.36% (11/89) were pre-extensively drug-resistant TB (pre-XDR-TB) and 77.53% (69/89) were XDR-TB. The <em>rrs</em> mutations were found 82.02% (73/89) in amikacin-resistant <em>M. tuberculosis</em> clinical isolates. The A1401 G alteration in <em>rrs</em> gene was the most dominant mutation (80.90%; 72/89). Five mutations were detected as new in <em>rrs</em>, <em>tap</em>, and <em>whiB7</em>. Notably, 13.48% (12/89) amikacin-resistant isolates had no known mutation in these genes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>Our data reveal that the <em>rrs</em> mutation is a predominant molecular marker of amikacin resistance in southern China. Analysis of the <em>rrs</em> gene mutations will significantly reduce the time and cost to diagnose amikacin resistance in TB patients. Other unknown amikacin resistance mechanism(s) exist.</p>
pharmacology & pharmacy,infectious diseases